Akari Therapeutics establishes Boston office as US headquarters
This office supports Akari’s current expansion of operations as the company prepares to start of enrollment in 2 registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and the start of PAS-nomacopan clinical trials in GA.
Akari Therapeutics establishes a Boston Seaport area office serving as the company’s US headquarters. (Image Credit: ©SeanPavonePhoto - Adobe.Stock.com)
Akari Therapeutics establishes a Boston Seaport area office serving as the company’s US headquarters.
This office supports Akari’s current expansion of operations as the company prepares to start of enrollment in 2 registrational nomacopan Phase 3 clinical trials in pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and the start of PAS-nomacopan clinical trials in geographic atrophy (GA). Enrollment in the Phase 3 clinical trials of nomacopan in pediatric and adult HSCT-TMA is expected to begin in late 2023 and 2024, respectively. The start of clinical trials of long-acting PAS-nomacopan as a potential treatment for GA is anticipated in 2024.1
Rachelle Jacques, Akari President and CEO, noted why the company has chosen Boston and the value of a US headquarters. In the news release1, she said, “Boston is a vibrant epicenter of biotech innovation in the U.S. providing Akari access to world-class talent and other resources as we continue to build our U.S. capabilities, advance our pivotal clinical trials, and work to realize the promise of nomacopan on behalf of patients and our investors.”
About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA and orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation. Akari’s pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.
Reference:
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials. August 18, 2023. Accessed September 5, 2023. http://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-announces-establishment-boston-us
